The Phase 3 TRANSFORM-1 study (NCT04472598) evaluated ruxolitinib (RUX) in combination with navitoclax (NAV) or placebo (PBO) in Janus-kinase-inhibitor-naïve adults with intermediate-2 or high-risk myelofibrosis and Eastern Cooperative Oncology Group performance status ≤2. Patients were randomized 1:1 to NAV (200 mg/day starting dose or 100 mg escalated to 200 mg/day) or PBO, with RUX dosed per label. The primary endpoint was ≥35% spleen volume reduction (SVR) at Week 24 (SVR35W24). Secondary endpoints included change from baseline in Total Symptom Score (TSS) at Week 24 and SVR35 at any time. A total of 252 patients (NAV+RUX, n=125; PBO+RUX, n=127; median follow-up 20.3 months) were randomized; >80% had intermediate-2 risk and nearly 50% were high-molecular risk (HMR). SVR35W24 was achieved by 63.2% with NAV+RUX versus 31.5% with PBO+RUX (P<0.0001). Mean change in TSS at Week 24 was not significantly different between NAV+RUX and PBO+RUX (-10.2 vs -11.6; P=0.2852). SVR35 at any time was achieved in 76.8% with NAV+RUX versus 44.1% with PBO+RUX (nominal P<0.0001). A ≥20% variant allele frequency reduction (exploratory endpoint) occurred in 58.5% (95% CI: 49.0-67.5) with NAV+RUX and 45.5% (95% CI: 36.4-54.8) with PBO+RUX. NAV+RUX showed higher hematologic toxicity versus PBO+RUX (Grade 3/4 thrombocytopenia: 54.0% vs 19.2%; Grade 3/4 neutropenia: 40.3% vs 8.8%); diarrhea (any grade: 41.9% vs 16.8%) was also more common. Cytopenias were generally manageable and reversible with dose adjustments.
720 Background: Digital patient navigation can engage patients with cancer across settings, but patient-initiated navigation alone may not overcome structural barriers to subspecialty consultation, trial access, and local-academic care coordination. Building on prior work showing high engagement but limited downstream subspecialty consultation through patient-facing navigation among patients with melanoma, we implemented a clinician-facing, HIPAA-compliant Shared Care Network (SCN) to connect academic subspecialists and community oncologists across mid-Atlantic practices. We evaluated feasibility and early utility. Methods: We retrospectively evaluated the first 228 cases managed through the SCN (6 academic, 18 community organizations) from January 2025 to May 2026. Outcomes were evaluated using RE-AIM, focusing on Reach (case volume and tumor-type distribution), Effectiveness (travel time saved via local coordination and proportion of completed subspecialty consults resulting in a documented care-plan change, including therapy modification, sequencing change, or trial referral), and Adoption (new physician relationships and case initiation by setting). Data sources included platform case logs, consult recommendations, treatment decision tracking, and mileage mapping. Results: Among 228 cases, 84% were initiated by community oncologists for trial matching (60%, n=137) or informal/formal subspecialty consultation (24%, n=55), and 16% (n=36) by academic oncologists for local care coordination. Median consult response time was 2.5 hours. Among 72 unique oncologist interactions, 70% (n=50) were new relationships. Most common tumor types were advanced skin cancers (36%, n=81), gastrointestinal cancers (25%, n=56), lung cancer (11%, n=24), breast cancer (9%, n=20), genitourinary cancers (5%, n=12), hematologic malignancies (4%, n=8). Among formal subspecialty consultations (n=40), 68% (n=27) had a documented treatment decision change. Of 23 patients completing a trial screening visit via SCN referral, 11 (48%) enrolled. In locally coordinated cases with mileage data (n=29), patients saved a median of 1.5 hours driving per visit. Conclusions: In this early implementation evaluation, a clinician-facing digital Shared Care Network facilitated academic-community collaboration, with most cases initiated by community oncologists and most oncologist interactions representing new relationships. Subspecialty input frequently changed care plans, and local coordination reduced travel burden. These findings suggest that embedding clinician-facing coordination into existing workflows may address referral, trial access, and geographic barriers not overcome by patient-facing navigation alone. Prospective RE-AIM evaluation is underway assessing implementation fidelity, maintenance, trial enrollment, and scalability.
OBJECTIVES:Intraoperative assessment of resection margins during pulmonary resection is limited by tissue compression and distortion caused by conventional staplers, which hinder direct pathological evaluation of the anatomical resection margin. We report our initial clinical experience with a novel asymmetric linear stapler (NALS) designed to provide direct access to the specimen-side anatomical resection margin for intraoperative histologic assessment. METHODS:We retrospectively reviewed patients who underwent pulmonary resection using the NALS between July 2024 and December 2025. Intraoperative frozen-section examination was performed for parenchymal and/or bronchial margins when malignancy was suspected or confirmed. Margin status, margin distance, and frozen-permanent pathological concordance were analysed descriptively. RESULTS:Among 226 patients who underwent pulmonary resection using the NALS, 206 resection margins (144 parenchymal and 62 bronchial) were evaluated. Intraoperative frozen-section examination identified margin positivity in 12 margins (5.8%). Residual tumour was confirmed on permanent pathology in 4 of 8 parenchymal frozen-positive margins, whereas all bronchial frozen-positive margins showed benign or reactive changes. No false-negative frozen-section findings were identified. Among negative margins with available measurements, 66.7% of parenchymal margins and 84.5% of bronchial margins measured at least 10 mm. CONCLUSIONS:In this initial experience, intraoperative margin assessment using the NALS was feasible and enabled structured evaluation of the anatomical resection margin during pulmonary resection. Because no control group using conventional staplers was included, these findings should be interpreted as a feasibility assessment rather than evidence of superiority over standard stapling devices. Further multicentre studies with controlled comparisons and long-term oncologic follow-up are warranted.